Effect of ipragliflozin on liver function in japanese type 2 diabetes mellitus patients: A subgroup analysis of the STELLA-LONG TERM study (3-month interim results)

Endocrine Journal

Volumn 66, Issue 1, 2019, Pages 31-41

  Tabuchi, Hiromi ^a   Maegawa, Hiroshi ^b   Tobe, Kazuyuki ^c   Nakamura, Ichiro ^a   Uno, Satoshi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Ipragliflozin; Japan; Liver function; Post marketing surveillance; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IPRAGLIFLOZIN; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ASIAN CONTINENTAL ANCESTRY GROUP; JAPAN; LIVER; LIVER FUNCTION TEST; METABOLISM; NONALCOHOLIC FATTY LIVER;

AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUCOSIDES; HUMANS; JAPAN; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PRODUCT SURVEILLANCE, POSTMARKETING; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; THIOPHENES;

EID: 85060605141     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ18-0217     Document Type: Article

References (33)

1. Cusi K (2016) Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 59: 1112–1120.
2. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212–1218.
3. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, et al. (2015) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100: 2231–2238.
4. Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, et al. (2014) Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multidisciplinary team approach to diagnosis and management. QJM 107: 33–41.
5. Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, et al. (2012) Prevalence and markers of advanced liver disease in type 2 diabetes. QJM 105: 425–432.
6. Baffy G (2013) Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention. J Clin Transl Hepatol 1: 131–137.
7. Lonardo A, Sookoian S, Pirola CJ, Targher G (2016) Nonalcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65: 1136–1150.
8. Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313: 2263–2273.
9. Poole RM, Dungo RT (2014) Ipragliflozin: first global approval. Drugs 74: 611–617.
10. Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, et al. (2016) Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: a subgroup analysis of five randomized clinical trials. J Diabetes Investig 7: 544–554.
11. Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, et al. (2016) Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol 51: 1141–1149.
12. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, et al. (2016) The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 11: e0146337.
13. Uchida J, Kabeya Y, Oikawa Y, Tanaka H, Atsumi Y, et al. (2016) The ameliorating effect of ipragliflozin, a SGLT2 inhibitor, on liver function without dependence on the body weight reduction. Journal of the Japan Diabetes Society 59: 782–790 (In Japanese).
14. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, et al. (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of nonalcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8: 45.
15. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, et al. (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11: e0151511.
16. Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, et al. (2015) Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754: 19–24.
17. Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, et al. (2015) Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 7: 104.
18. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, et al. (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727: 66–74.
19. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, et al. (2014) Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 4: e125.
20. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715: 246–255.
21. Maegawa H, Tobe K, Tabuchi H, Nakamura I (2016) Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opin Pharmacother 17: 1985–1994.
22. Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S (2018) Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM postmarketing surveillance study. Expert Opin Pharmacother 19: 189–201.
23. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, et al. (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.
24. Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, et al. (2017) Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res 9: 586–595.
25. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y (2017) Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 87: 13–19.
26. Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, et al. (2018) Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 53: 140–151.
27. Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, et al. (2016) Effects of sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 diabetes: a chart-based analysis. J Clin Med Res 8: 237–243.
28. Lowe D, John S [Updated 2017 Oct 22] Alkaline Phos‐ phatase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan. Available from: https: // www.ncbi.nlm.nih.gov/books/NBK459201/
29. Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T (2017) Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J 64: 363–367.
30. Ohta A, Kato H, Ishii S, Sasaki Y, Nakamura Y, et al. (2017) Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother 18: 1433–1438.
31. Ko YH, Wong TC, Hsu YY, Kuo KL, Yang SH (2017) The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease. Metab Syndr Relat Disord 15: 304–311.
32. Yadav D, Choi E, Ahn SV, Koh SB, Sung KC, et al. (2016) Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study. Medicine (Baltimore) 95: e4447.
33. Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, et al. (2017) Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 40: 1364–1372.